MENU
+Compare
FOLD
Stock ticker: NASDAQ
AS OF
Sep 18, 02:01 PM (EDT)
Price
$8.34
Change
+$0.37 (+4.64%)
Capitalization
2.47B

FOLD Amicus Therapeutics Forecast, Technical & Fundamental Analysis

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases... Show more

Industry: #Biotechnology
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for FOLD with price predictions
Sep 17, 2025

FOLD saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for FOLD moved out of overbought territory on September 10, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 54 similar instances where the indicator exited the overbought zone. In of the 54 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for FOLD moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for FOLD turned negative on September 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOLD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FOLD broke above its upper Bollinger Band on September 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FOLD advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 177 cases where FOLD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FOLD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.019) is normal, around the industry mean (19.637). P/E Ratio (0.000) is within average values for comparable stocks, (53.583). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.168). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (4.279) is also within normal values, averaging (331.570).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

FOLD is expected to report earnings to rise 134.00% to 2 cents per share on November 05

Amicus Therapeutics FOLD Stock Earnings Reports
Q3'25
Est.
$0.02
Q2'25
Beat
by $0.12
Q1'25
Beat
by $0.05
Q4'24
Beat
by $0.08
Q3'24
Beat
by $0.10
The last earnings report on July 31 showed earnings per share of 0 cents, beating the estimate of -10 cents. With 2.89M shares outstanding, the current market capitalization sits at 2.47B.
A.I. Advisor
published General Information

General Information

a developer of orally active drugs to treat human genetic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
47 Hulfish Street
Phone
+1 609 662-2000
Employees
517
Web
https://www.amicusrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SCICX58.170.54
+0.94%
Columbia Seligman Tech & Info C
GERCX10.81N/A
N/A
Goldman Sachs Em Mkts Eq Insghts C
AHSCX11.85N/A
N/A
Alger Health Sciences C
EILGX19.57N/A
N/A
Eaton Vance Atlanta Capital Focused Gr I
LGCSX20.14N/A
N/A
Lord Abbett Global Equity R4

FOLD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
-0.50%
VCYT - FOLD
43%
Loosely correlated
-1.36%
ATXS - FOLD
42%
Loosely correlated
+1.79%
IRON - FOLD
40%
Loosely correlated
+1.15%
SYRE - FOLD
40%
Loosely correlated
+1.82%
ROIV - FOLD
40%
Loosely correlated
+7.72%
More